186 related articles for article (PubMed ID: 37903311)
1. AMPK activation induces immunogenic cell death in AML.
Mondesir J; Ghisi M; Poillet L; Bossong RA; Kepp O; Kroemer G; Sarry JE; Tamburini J; Lane AA
Blood Adv; 2023 Dec; 7(24):7585-7596. PubMed ID: 37903311
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
3. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
4. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
5. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
Front Immunol; 2021; 12():695051. PubMed ID: 34413848
[TBL] [Abstract][Full Text] [Related]
6. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.
Nieda M; Nicol A; Koezuka Y; Kikuchi A; Lapteva N; Tanaka Y; Tokunaga K; Suzuki K; Kayagaki N; Yagita H; Hirai H; Juji T
Blood; 2001 Apr; 97(7):2067-74. PubMed ID: 11264173
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapies in the treatment of AML: is there hope?
Subklewe M; Bücklein V; Sallman D; Daver N
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):691-701. PubMed ID: 38066884
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
9. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
10. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia.
Agrawal V; Gbolahan OB; Stahl M; Zeidan AM; Zaid MA; Farag SS; Konig H
Curr Cancer Drug Targets; 2020; 20(7):473-489. PubMed ID: 32357813
[TBL] [Abstract][Full Text] [Related]
11. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
12. Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.
Sujobert P; Poulain L; Paubelle E; Zylbersztejn F; Grenier A; Lambert M; Townsend EC; Brusq JM; Nicodeme E; Decrooqc J; Nepstad I; Green AS; Mondesir J; Hospital MA; Jacque N; Christodoulou A; Desouza TA; Hermine O; Foretz M; Viollet B; Lacombe C; Mayeux P; Weinstock DM; Moura IC; Bouscary D; Tamburini J
Cell Rep; 2015 Jun; 11(9):1446-57. PubMed ID: 26004183
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
14. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
[TBL] [Abstract][Full Text] [Related]
15. AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
Grenier A; Poulain L; Mondesir J; Jacquel A; Bosc C; Stuani L; Mouche S; Larrue C; Sahal A; Birsen R; Ghesquier V; Decroocq J; Mazed F; Lambert M; Andrianteranagna M; Viollet B; Auberger P; Lane AA; Sujobert P; Bouscary D; Sarry JE; Tamburini J
Cell Rep; 2022 Jan; 38(1):110197. PubMed ID: 34986346
[TBL] [Abstract][Full Text] [Related]
16. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
19. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
